GlassScriptPhysician profile
Molly Strattan
NPI 1104903731
$5,047.41
in general payments reported to CMS, 2019-2025
34 companies · $766 in 2025
The $766 reported for 2025 was more than what 98% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $748 · 2023: $1,249 · 2024: $1,116 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,975.21 |
| Education | $155.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,642.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $365.53 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $352.47 | 2023-2025 | Veozah |
| Novo Nordisk INC | $258.61 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.16 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $227.97 | 2021-2025 | Emgality, Jardiance, Mounjaro |
| Exact Sciences Corporation | $194.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $174.53 | 2021-2025 | Airsupra, Breztri |
| Abbott Laboratories | $162.01 | 2021-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $158.01 | 2024-2025 | Cobenfy, Camzyos |
| Otsuka America Pharmaceutical, INC. | $135.76 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Aimmune Therapeutics, INC. | $105.53 | 2024-2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $102.35 | 2021-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $95.21 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $88.36 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $83.02 | 2025 | Rezdiffra |
| Organon LLC | $81.99 | 2021-2025 | Nexplanon |
| Pfizer INC. | $77.61 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $57.03 | 2021 | |
| Phathom Pharmaceuticals, INC. | $50.33 | 2024-2025 | Voquezna |
| Bausch Health US, LLC | $49.15 | 2021-2022 | |
| Evofem Biosciences, INC. | $47.10 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.28 | 2024 | Caplyta |
| Celgene Corporation | $33.21 | 2021 | |
| Therapeuticsmd, INC. | $32.81 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $31.77 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $24.45 | 2022 | |
| Ironshore Pharmaceuticals INC. | $24.40 | 2022 | |
| Nevro Corp. | $22.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.05 | 2021 | |
| Lucid Diagnostics INC. | $15.38 | 2022 | |
| Alkermes, INC. | $13.90 | 2023 | Lybalvi |
| Kowa Pharmaceuticals America, INC. | $13.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Strattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.